PURPOSE:Tamoxifen and fenretinide are active in reducing premenopausal breast cancer risk and work synergistically in preclinical models. The authors assessed their combination in a two-by-two biomarker trial. PATIENTS AND METHODS: A total of 235 premenopausal women with pT1mic/pT1a breast cancer (n = 21), or intraepithelial neoplasia (IEN, n = 160), or 5-year Gail risk > or = 1.3% (n = 54) were randomly allocated to either tamoxifen 5 mg/d, fenretinide 200 mg/d, their combination, or placebo. We report data for plasma insulin-like growth factorI (IGF-I), mammographic density, uterine effects, and breast neoplastic events after 5.5 years. RESULTS: During the 2-year intervention, tamoxifen significantly lowered IGF-I and mammographic density by 12% and 20%, respectively, fenretinide by 4% and 10% (not significantly), their combination by 20% and 22%, with no evidence for a synergistic interaction. Tamoxifen increased endometrial thickness principally in women becoming postmenopausal, whereas fenretinide decreased endometrial thickness significantly. The annual rate of breast neoplasms (n = 48) was 3.5% +/- 1.0%, 2.1% +/- 0.8%, 4.7% +/- 1.3%, and 5.2% +/- 1.3% in the tamoxifen, fenretinide, combination, and placebo arms, respectively, with hazard ratios (HRs) of 0.70 (95% CI, 0.32 to 1.52), 0.38 (95% CI, 0.15 to 0.90), and 0.96 (95% CI, 0.46 to 1.99) relative to placebo (tamoxifen x fenretinide adverse interaction P = .03). There was no clear association with tumor receptor type. Baseline IGF-I and mammographic density did not predict breast neoplastic events, nor did change in mammographic density. CONCLUSION: Despite favorable effects on plasma IGF-I levels and mammographic density, the combination of low-dose tamoxifen plus fenretinide did not reduce breast neoplastic events compared to placebo, whereas both single agents, particularly fenretinide, showed numerical reduction in annual odds of breast neoplasms. Further follow-up is indicated.
RCT Entities:
PURPOSE:Tamoxifen and fenretinide are active in reducing premenopausal breast cancer risk and work synergistically in preclinical models. The authors assessed their combination in a two-by-two biomarker trial. PATIENTS AND METHODS: A total of 235 premenopausal women with pT1mic/pT1a breast cancer (n = 21), or intraepithelial neoplasia (IEN, n = 160), or 5-year Gail risk > or = 1.3% (n = 54) were randomly allocated to either tamoxifen 5 mg/d, fenretinide 200 mg/d, their combination, or placebo. We report data for plasma insulin-like growth factor I (IGF-I), mammographic density, uterine effects, and breast neoplastic events after 5.5 years. RESULTS: During the 2-year intervention, tamoxifen significantly lowered IGF-I and mammographic density by 12% and 20%, respectively, fenretinide by 4% and 10% (not significantly), their combination by 20% and 22%, with no evidence for a synergistic interaction. Tamoxifen increased endometrial thickness principally in women becoming postmenopausal, whereas fenretinide decreased endometrial thickness significantly. The annual rate of breast neoplasms (n = 48) was 3.5% +/- 1.0%, 2.1% +/- 0.8%, 4.7% +/- 1.3%, and 5.2% +/- 1.3% in the tamoxifen, fenretinide, combination, and placebo arms, respectively, with hazard ratios (HRs) of 0.70 (95% CI, 0.32 to 1.52), 0.38 (95% CI, 0.15 to 0.90), and 0.96 (95% CI, 0.46 to 1.99) relative to placebo (tamoxifen x fenretinide adverse interaction P = .03). There was no clear association with tumor receptor type. Baseline IGF-I and mammographic density did not predict breast neoplastic events, nor did change in mammographic density. CONCLUSION: Despite favorable effects on plasma IGF-I levels and mammographic density, the combination of low-dose tamoxifen plus fenretinide did not reduce breast neoplastic events compared to placebo, whereas both single agents, particularly fenretinide, showed numerical reduction in annual odds of breast neoplasms. Further follow-up is indicated.
Authors: I Cohen; E Perel; R Tepper; D Flex; A Figer; J Shapira; M M Altaras; A Fishman; J Bernheim; M Cordoba; D Yigael; Y Beyth Journal: Breast Cancer Res Treat Date: 1999-02 Impact factor: 4.872
Authors: S E Hankinson; W C Willett; G A Colditz; D J Hunter; D S Michaud; B Deroo; B Rosner; F E Speizer; M Pollak Journal: Lancet Date: 1998-05-09 Impact factor: 79.321
Authors: Eva S Schernhammer; Jeff M Holly; Michael N Pollak; Susan E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-03 Impact factor: 4.254
Authors: R Torrisi; S Parodi; V Fontana; F Pensa; C Casella; A Barreca; G De Palo; A Costa; A Decensi Journal: Int J Cancer Date: 1998-06-10 Impact factor: 7.396
Authors: J R Hilditch; J Lewis; A Peter; B van Maris; A Ross; E Franssen; G H Guyatt; P G Norton; E Dunn Journal: Maturitas Date: 1996-07 Impact factor: 4.342
Authors: A Decensi; B Bonanni; A Guerrieri-Gonzaga; S Gandini; C Robertson; H Johansson; R Travaglini; M T Sandri; A Tessadrelli; G Farante; F Salinaro; D Bettega; A Barreca; P Boyle; A Costa; U Veronesi Journal: J Natl Cancer Inst Date: 1998-10-07 Impact factor: 13.506
Authors: I F Pollack; R C DaRosso; P L Robertson; R L Jakacki; J R Mirro; J Blatt; S Nicholson; R J Packer; J C Allen; A Cisneros; V C Jordan Journal: Clin Cancer Res Date: 1997-07 Impact factor: 12.531
Authors: Sarah J Nyante; Mark E Sherman; Ruth M Pfeiffer; Amy Berrington de Gonzalez; Louise A Brinton; Erin J Aiello Bowles; Robert N Hoover; Andrew Glass; Gretchen L Gierach Journal: J Natl Cancer Inst Date: 2015-02-06 Impact factor: 13.506
Authors: Ruta D Rao; Melody A Cobleigh; Robert Gray; Mark L Graham; Larry Norton; Silvana Martino; George Thomas Budd; James N Ingle; William C Wood Journal: Med Oncol Date: 2010-09-28 Impact factor: 3.064
Authors: Richard A Graves; Grace A Ledet; Elena Y Glotser; Demaurian M Mitchner; Levon A Bostanian; Tarun K Mandal Journal: Eur J Pharm Sci Date: 2015-04-28 Impact factor: 4.384
Authors: Cynthia A Thomson; H H Sherry Chow; Betsy C Wertheim; Denise J Roe; Alison Stopeck; Gertraud Maskarinec; Maria Altbach; Pavani Chalasani; Chuan Huang; Meghan B Strom; Jean-Philippe Galons; Patricia A Thompson Journal: Breast Cancer Res Treat Date: 2017-05-30 Impact factor: 4.872